GH - Guardant Health, Inc.
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) will be covered in Carelon Healthcare Services clinical guidelines effective November 15. Carelon Healthcare Services is one of the largest specialty benefits managers in the country and subsidiary of one of the largest health insurance companies in the U.S spanning more than 14 states. The new policy update fr.
You found a great company, then watched it double before you got round to buying.
Bamco Inc. NY bought a new stake in Guardant Health, Inc. (NASDAQ: GH) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 16,500 shares of the company's stock, valued at approximately $2,475,000. A number of other institutional investors have also modified their holdings
Callan Family Office LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ: GH) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 6,080 shares of the company's stock, valued at approximately $912,000. A number of other institutional investors and
On August 24, 2026, Guardant Health Inc (GH) shares fell 4.4% to a current price of $163.18, reflecting a volatile trading environment. The stock has experience
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. “We strongly disagree with this decision and will prompt.
A Delaware federal judge finalized a ruling ordering Guardant Health (NASDAQ:GH) to pay over $245.2 million to TwinStrand Biosciences and the University of Washington, cementing a November 2023 jury verdict that found Guardant willfully infringed on two Duplex Sequencing patents.
Guardant Health NASDAQ: GH highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs Helmy Eltoukhy and AmirAli Talasaz pointing to expanding adoption, new reimbursement developments, and planned product launches.
Guardant Health, Inc. (GH) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.
Guardant Health is experiencing robust growth, driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help to ensure growth remains strong going forward. Competition in both screening and MRD monitoring is set to intensify in coming years, though.
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 21, 2026, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 46,044 shares of its common stock to 149 new non-executive employees with a grant date of August 3, 2026, under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”). The RSUs.
Empowered Funds LLC trimmed its holdings in Guardant Health, Inc. (NASDAQ: GH) by 81.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 13,457 shares of the company's stock after selling 58,422 shares during the quarter. Empowered Funds LLC's holdings in
Dimensional Fund Advisors LP lowered its position in Guardant Health, Inc. (NASDAQ: GH) by 40.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 182,727 shares of the company's stock after selling 123,826 shares during the quarter. Dimensional Fund Advisors LP owned about
On August 06, 2026, Guardant Health Inc (GH) shares fell 3.4% today, trading at $157.58. Over the past 52 weeks, the stock has ranged from a low of $43.66 to a
Three of these watchlist stocks have already passed their earnings tests.
AngloGold Ashanti plc (âAngloGold Ashantiâ, âAGAâ, the âCompanyâ or the âGroupâ) said Q2 2026 free cash flow* rose 36% year-on-year to $727m, fu
Guardant Health, Inc. (GH) Q2 2026 Earnings Call Transcript